PLIANT THERAPEUTICS, INC. 8-K

What Happened
Pliant Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 in a press release dated May 11, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8-K filed May 11, 2026. The filing notes the furnished press release is not “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.

Key Details

• Event: Results of Operations and Financial Condition disclosed (Item 2.02).
• Press release furnished as Exhibit 99.1 to the Form 8-K (filed May 11, 2026).
• Reporting period: quarter ended March 31, 2026.
• Form 8-K signed by Keith Cummings, M.D., MBA, Chief Financial Officer.

Why It Matters
This 8-K signals that Pliant has released its latest quarterly results and that investors should review the May 11 press release for specifics on revenue, expenses, cash position, and any operational or program updates. The press release is the immediate source for the company’s reported quarterly performance; additional details and reconciliations will typically follow in the company’s quarterly report (Form 10-Q).